DBV Technologies Q2 Earnings Call Highlights

DBV Technologies is preparing to file a BLA for its VIASKIN Peanut Patch in Q3 2026 and said it may request priority review, with the FDA process still on track and no request for additional clinical data. The company is expanding its peanut allergy program beyond children ages 4 to 7, with recruitment closed for the COMFORT Toddlers safety study, a planned filing for ages 1 to 3 by year-end 2026, and the first infant patient enrolled in the new THRIVE Phase 2 study. DBV is also building commercial readiness for a potential U.S. launch, including market access, patient services, supply chain, and launch operations, and said it has funding into Q3 2027.

DBV Technologies NASDAQ: DBVT said it is continuing preparations for a planned third-quarter 2026 Biologics License Application submission for its VIASKIN Peanut Patch in children ages 4 through 7, while also building commercial infrastructure ahead of a potential U.S. launch. On a conference call discussing second-quarter and first-half 2026 results, Chief Executive Officer Daniel Tassé said the company is working to “transform the company into a commercial organization” in anticipation of possible FDA approval of the patch. The company’s lead program is aimed at treating peanut allergy in children.

Tassé said DBV is still optimizing its BLA submission through discussions with the FDA, which he characterized as constructive and collaborative. He emphasized that the agency has not asked for additional data. “The work underway is focused on incorporating FDA feedback related to the organization, the mapping, and formatting of existing CMC and biostatistical data sets,” Tassé said. He added that DBV plans to submit an “optimized BLA” in the third quarter of 2026 to support an efficient review.

During the question-and-answer portion of the call, Tassé said DBV plans to request priority review when it files the BLA because the VIASKIN Peanut platform has breakthrough designation, making the company eligible to seek that review pathway. He said the FDA has up to 60 days after filing to accept the application for review and to determine whether priority review will be granted. DBV is currently assuming the full 60-day period, though Tassé said there is a possibility the timeline could be shorter given the level of engagement with the agency. If granted, priority review would mean a six-month review period.

On chemistry, manufacturing and controls, Tassé said discussions with the FDA are “essentially now completed” and that the agency’s comments do not require changes to how DBV manufactures the product. “There’s nothing that the agency has asked us to do that represents a change in any way, shape, or form to the way we manufacture the product,” he said. Asked what remains before submission, Tassé said the gating items are completing discussions with the FDA on CMC and on the formatting and tabulation of biostatistics tables.

Chief Medical Officer Pharis Mohideen said DBV closed recruitment during the second quarter for COMFORT Toddlers, a supplemental safety study evaluating VIASKIN Peanut in toddlers ages 1 to 3. In response to an analyst question, Mohideen said the study includes a six-month treatment period and has no efficacy component. Tassé said DBV still intends to file for the 1-to-3-year-old population by the end of 2026. He noted that EPITOPE, the pivotal trial in that age group, has already been completed and showed efficacy. Mohideen also highlighted additional presentations from the VITESSE Phase 3 study in 4-to-7-year-olds.